John Mcgrath Sells 5,000 Shares of Atara Biotherapeutics Inc. (ATRA) Stock
Atara Biotherapeutics Inc. (NASDAQ:ATRA) CFO John Mcgrath sold 5,000 shares of Atara Biotherapeutics stock in a transaction on Wednesday, October 12th. The shares were sold at an average price of $17.47, for a total value of $87,350.00. Following the completion of the transaction, the chief financial officer now owns 96,823 shares of the company’s stock, valued at $1,691,497.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) opened at 16.15 on Tuesday. Atara Biotherapeutics Inc. has a 12-month low of $13.31 and a 12-month high of $40.80. The firm’s market capitalization is $465.30 million. The stock’s 50 day moving average price is $19.53 and its 200-day moving average price is $20.24.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. On average, equities analysts expect that Atara Biotherapeutics Inc. will post ($2.85) EPS for the current year.
A number of analysts have weighed in on ATRA shares. Jefferies Group restated a “buy” rating and issued a $25.00 price target on shares of Atara Biotherapeutics in a research note on Tuesday, August 9th. JMP Securities restated a “buy” rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 2nd. Goldman Sachs Group Inc. cut Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their price target for the company from $23.00 to $16.00 in a research report on Thursday, September 15th. Finally, Citigroup Inc. boosted their price target on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research report on Friday, August 19th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $26.14.
A number of institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in Atara Biotherapeutics by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 62,600 shares of the company’s stock worth $1,191,000 after buying an additional 1,900 shares during the last quarter. A.R.T. Advisors LLC increased its position in Atara Biotherapeutics by 79.6% in the first quarter. A.R.T. Advisors LLC now owns 63,941 shares of the company’s stock worth $1,216,000 after buying an additional 28,330 shares in the last quarter. Bridger Management LLC acquired a new position in Atara Biotherapeutics during the first quarter worth $14,072,000. Bank of New York Mellon Corp increased its position in Atara Biotherapeutics by 20.9% in the second quarter. Bank of New York Mellon Corp now owns 99,629 shares of the company’s stock worth $2,243,000 after buying an additional 17,195 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in Atara Biotherapeutics by 35.3% in the second quarter. California State Teachers Retirement System now owns 48,704 shares of the company’s stock worth $1,096,000 after buying an additional 12,704 shares in the last quarter. 75.58% of the stock is owned by hedge funds and other institutional investors.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.